Feedback requested for the scope of revision of the NICE CKD guideline

NICE are planning an update to the CKD guideline in 2019-20 and recently announced the planned scope of the update. This involves partial updates and amalgamation of "Chronic kidney disease in adults: assessment and management (CG182)", "Chronic kidney disease (stage 4 or 5): management of hyperphosphataemia (CG157)" and "Chronic kidney disease: managing anaemia (NG8)". The new guideline will be extended to cover children and young people.

The Renal Association, together with stakeholders from the NHS, third sector, other professional societies and industry, was represented at a consultation on the draft guideline scope at a workshop held on 12th November 2018.

The new guideline will not review all areas but will focus on topics where it has been identified that the evidence base has progressed since the last update, or where new guidance is needed. The areas NICE have at present selected to focus on are:

1. Investigations for CKD in adults, children and young people
   - When to use a cystatin C-based estimate of GFR for diagnosis of CKD
   - When to test for proteinuria in children and young people
   - When to test for haematuria in children and young people
   - Which children and young people should be tested for CKD?

2. Classification of CKD in adults, children and young people
   - Classification of CKD
   - Determining the risk of adverse outcomes

3. Frequency of monitoring in adults, children and young people
   - Defining progression of CKD

4. Management of mineral and bone disorder in chronic kidney disease in adults, children and young people
   - The use of calcium and non-calcium containing phosphate binders to manage mineral and bone disorder in chronic kidney disease

5. Diagnostic evaluation and assessment of anaemia
   - Diagnostic role of glomerular filtration rate

6. Managing anaemia
   - IV Iron for the treatment of anaemia associated with CKD

NICE are also planning a partial update of "Acute kidney injury: prevention, detection and management (CG169)", specifically centred on a review of evidence of the clinical and cost-effectiveness of IV fluids and NAC for the prevention of contrast-induced nephropathy.

The Renal Association are seeking input from all members into the planned changes. The full report of the scope of the planned update is attached. At present there is still the possibility of NICE including additional areas if they recognise that they have overlooked important new evidence, or changing the focus on selected topics. Please send any comments about the CKD scope to laurie.tomlinson@lshtm.ac.uk and the AKI scope to suren.kanagasundaram@newcastle.ac.uk who will collate these. The end of the consultation period is 11th January 2019 so please send any comments by 1st January 2019 to allow time for these to be processed. NICE will not accept comments from individuals, only registered stakeholders.

The scope will be opened up for general consultation in December when invitations for guideline committee membership will also be extended. We'll be posting further updates via the Newsletter and on the RA website.